Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.47 |
| ▸ | PGR | P06401 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.47 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.43 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29607568 | 1.00 | LMNA (0.47) | LMNAHTTNR1I2PGRCYP3A4 | |
| SCHEMBL6807798 | 1.00 | LMNA (0.47) | LMNAHTTNR1I2PGRCYP3A4 | |
| SCHEMBL5474595 | 0.87 | LMNA (0.53) | LMNAHTTNR1I2PGRCYP3A4 | |
| SCHEMBL5474591 | 0.87 | LMNA (0.53) | LMNAHTTNR1I2PGRCYP3A4 | |
| SCHEMBL23582633 | 0.87 | LMNA (0.45) | LMNAHTTNR1I2PGRCYP3A4 | |
| SCHEMBL18046427 | 0.85 | BACE1 (0.54) | LMNAHTTNR1I2PGRCYP3A4 | |
| SCHEMBL18046430 | 0.85 | BACE1 (0.54) | LMNAHTTNR1I2PGRCYP3A4 | |
| SCHEMBL5457635 | 0.84 | CA1 (0.51) | LMNAHTTNR1I2PGRCYP3A4 | |
| SCHEMBL5457639 | 0.84 | CA1 (0.51) | LMNAHTTNR1I2PGRCYP3A4 | |
| SCHEMBL6799880 | 0.82 | TRPA1 (0.52) | LMNACYP2C9CYP2C19TRPA1TRPM8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11919839-B2 | Alpha-cinnamide compounds and compositions as HDAC8 inhibitors | VALO HEALTH, INC. (US) | 2024-03-05 | — | — | US | disclosed |
| US-20220073452-A1 | ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDAC8 INHIBITORS | VALO HEALTH, INC. | 2022-03-10 | — | — | US | disclosed |
| EP-3932914-A1 | ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDAC8 INHIBITORS | Valo Health, Inc. (US) | 2022-01-05 | — | — | EP | disclosed |
| US-10988441-B2 | Alpha-cinnamide compounds and compositions as HDAC8 inhibitors | VALO EARLY DISCOVERY, INC. (US) | 2021-04-27 | — | — | US | disclosed |
| US-20200331847-A1 | ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDAC8 INHIBITORS | VALO HEALTH, INC. | 2020-10-22 | — | — | US | disclosed |
| US-10508077-B2 | Alpha-cinnamide compounds and compositions as HDAC8 inhibitors | FORMA THERAPEUTICS, INC. (US) | 2019-12-17 | — | — | US | disclosed |
| US-20190241506-A1 | ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDAC8 INHIBITORS | VALO HEALTH, INC. | 2019-08-08 | — | — | US | disclosed |
| US-10266487-B2 | Alpha-cinnamide compounds and compositions as HDAC8 inhibitors | FORMA THERAPEUTICS, INC. (US) | 2019-04-23 | — | — | US | disclosed |
| US-20180297939-A1 | ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDAC8 INHIBITORS | Valo Health, LLC | 2018-10-18 | — | — | US | disclosed |
| US-20180044282-A1 | ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDAC8 INHIBITORS | VALO EARLY DISCOVERY, INC. | 2018-02-15 | — | — | US | disclosed |
| US-20160264518-A1 | ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDAC8 INHIBITORS | Valo Health, LLC | 2016-09-15 | — | — | US | disclosed |
| US-20040063959-A1 | Esters and amides as PLA2 inhibitors | FUKAMI NAOKI (JP) | 2004-04-01 | — | — | US | disclosed |
| US-20020169326-A1 | Esters and amides as PLA2 inhibitors | FUJISAWA PHARMACEUTICAL COMPANY, LTD. (JP) | 2002-11-14 | — | — | US | disclosed |
| EP-0854863-B1 | ESTERS AND AMIDES AS PLA2 INHIBITORS | FUJISAWA PHARMACEUTICAL CO (JP) | 2002-10-30 | — | — | EP | disclosed |
| US-20020019416-A1 | ESTERS AND AMIDES AS PLA2 INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-02-14 | — | — | US | disclosed |
| US-6207686-B1 | FOR THERAPY OF HYPERTENSION | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-03-27 | — | — | US | disclosed |
| EP-0854863-A1 | ESTERS AND AMIDES AS PLA2 INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-07-29 | — | — | EP | disclosed |
| EP-0792265-A1 | ENDOTHELIN ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-09-03 | — | — | EP | disclosed |
| WO-1997003951-A1 | ESTERS AND AMIDES AS PLA2 INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-02-06 | — | — | WO | disclosed |
| WO-1996015109-A1 | ENDOTHELIN ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180044282-A1 | ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDAC8 INHIBITORS | HDAC8, HDAC7, HDAC1 | LMNA 226/4885HTT 974/4885NR1I2 457/4885 |
| US-20220073452-A1 | ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDAC8 INHIBITORS | HDAC8, HDAC7, HDAC1 | LMNA 226/4885HTT 974/4885NR1I2 457/4885 |
| US-20200331847-A1 | ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDAC8 INHIBITORS | HDAC8, HDAC7, HDAC1 | LMNA 226/4885HTT 974/4885NR1I2 457/4885 |
| US-10988441-B2 | Alpha-cinnamide compounds and compositions as HDAC8 inhibitors | HDAC8, HDAC7, HDAC1 | LMNA 226/4885HTT 974/4885NR1I2 457/4885 |
| US-20040063959-A1 | Esters and amides as PLA2 inhibitors | PLA2G4A, PLA2G2D, PLA2G4B | LMNA 3118/4885HTT 3883/4885NR1I2 584/4885 |
| US-20160264518-A1 | ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDAC8 INHIBITORS | HDAC8, HDAC7, HDAC1 | LMNA 226/4885HTT 974/4885NR1I2 457/4885 |
| US-10508077-B2 | Alpha-cinnamide compounds and compositions as HDAC8 inhibitors | HDAC8, HDAC7, HDAC1 | LMNA 226/4885HTT 974/4885NR1I2 457/4885 |
| US-10266487-B2 | Alpha-cinnamide compounds and compositions as HDAC8 inhibitors | HDAC8, HDAC7, HDAC1 | LMNA 226/4885HTT 974/4885NR1I2 457/4885 |
| US-20020019416-A1 | ESTERS AND AMIDES AS PLA2 INHIBITORS | PLA2G4A, PLA2G4B, PLA2G1B | LMNA 3290/4885HTT 4127/4885NR1I2 468/4885 |
| US-20190241506-A1 | ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDAC8 INHIBITORS | HDAC8, HDAC7, HDAC1 | LMNA 226/4885HTT 974/4885NR1I2 457/4885 |
| US-11919839-B2 | Alpha-cinnamide compounds and compositions as HDAC8 inhibitors | HDAC8, HDAC7, HDAC1 | LMNA 226/4885HTT 974/4885NR1I2 457/4885 |
| US-20020169326-A1 | Esters and amides as PLA2 inhibitors | PLA2G4A, PLA2G2D, PLA2G4B | LMNA 3469/4885HTT 4083/4885NR1I2 554/4885 |
| US-20180297939-A1 | ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDAC8 INHIBITORS | HDAC8, HDAC7, HDAC1 | LMNA 226/4885HTT 974/4885NR1I2 457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.